Chinese infectious disease biotech Ascletis nabs Novartis exec as CSO

trump and xi plan no new tariffs
Chinese biotech Ascletis is hoping to become an international player, though trade tensions and political strife in China and Hong Kong are not making it easy. (Getty Images)

After poaching an ex-Merck exec to run its R&D, Chinese biotech Ascletis has raided another U.S. Big Pharma for its new chief scientific officer.

The company has poached Handan He, Ph.D., a 22-year veteran of Swiss major Novartis, as its new CSO. She was most recently the global head of computational, biopharmaceutics and translational PK/PD at Novartis where she managed scientific teams across the U.S. and Switzerland.

This comes half a year after Ascletis enticed another Big Pharma veteran to serve as its new CMO and head of R&D, attracting former MSD China global vice president Zhengqing Li, Ph.D., to the role.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Li has also served as general manager of MSD China’s R&D operations since 2011 and is credited with helping the Merck & Co. unit gain Chinese approval for more than 20 product filings, including checkpoint inhibitor Keytruda, hepatitis C treatment Zepatier and human papillomavirus vaccine Gardasil.

RELATED: Reality check for Hong Kong biotech IPOs as Ascletis slips

Ascletis has already bagged its first product approval in China for Ganovo (danoprevir), an NS3/4A protease inhibitor for hepatitis C virus infection that is the first directly acting antiviral to be commercialized by a domestic company in China.

Most of Ascletis’ near-term pipeline is directed firmly toward the domestic market, but the biotech’s longer-term challenge will be to help elevate Ascletis from a domestic to an international biopharma player.

That means advancing in-house drugs for hepatitis B virus and nonalcoholic steatohepatitis into clinical development, which are the immediate tasks for He and Li.

Last year, Ascletis was valued at around $2 billion after its initial public offering priced at the middle of an indicative range, but it was swiftly brought down to earth by a steep decline that hit many companies trading in Hong Kong.

The biotech hit a high of 8.45 Hong Kong dollars ($1.08) a share in March after hiring Li but has steadily fallen over the following months, worth just over 3 Hong Kong dollars yesterday with a market cap of around $440 million.

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.